MannKind Corp Financials

MNKD Stock  USD 6.11  0.02  0.33%   
Based on the analysis of MannKind Corp's profitability, liquidity, and operating efficiency, MannKind Corp may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At present, MannKind Corp's Other Assets are projected to decrease significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 322.4 M, whereas Retained Earnings are forecasted to decline to (3.1 B). Key indicators impacting MannKind Corp's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio3.274.12
Significantly Down
Slightly volatile
The financial analysis of MannKind Corp is a critical element in measuring its lifeblood. Investors should not minimize MannKind Corp's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(14.42 Million)

  
Please note, the presentation of MannKind Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MannKind Corp's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of MannKind Corp's management manipulating its earnings.

MannKind Corp Stock Summary

MannKind Corp competes with Biomarin Pharmaceutical, Vaxcyte, Liquidia Technologies, Legend Biotech, and Bio Techne. MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California. Mannkind Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 348 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS56400P7069
CUSIP56400P706 56400P201
LocationCalifornia; U.S.A
Business Address1 Casper Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.mannkindcorp.com
Phone818 661 5000
CurrencyUSD - US Dollar

MannKind Corp Key Financial Ratios

MannKind Corp Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets108.6M321.2M295.3M475.2M546.5M573.8M
Retained Earnings(3.0B)(3.1B)(3.2B)(3.2B)(2.9B)(3.1B)
Other Assets2.2M3.3M5.2M9.7M8.7M9.2M
Total Liab289.0M530.5M545.8M721.4M829.6M871.0M
Other Current Liab30.8M33.6M44.0M63.9M73.5M77.2M
Other Liab102.2M95.9M106.4M105.2M121.0M127.0M
Net Debt56.4M258.6M313.1M143.9M165.5M96.4M
Accounts Payable5.6M7.0M11.1M9.6M8.6M6.3M
Cash67.0M124.2M69.8M238.5M214.6M225.4M
Other Current Assets3.3M7.0M25.5M34.8M40.1M42.1M
Total Current Assets79.5M219.7M234.9M373.4M429.4M450.9M
Common Stock2.4M2.5M2.6M2.7M3.1M2.1M
Short Term Debt4.1M7.0M10.5M32.0M28.8M40.7M
Net Receivables4.2M5.0M16.8M14.9M17.1M18.0M
Inventory5.0M7.2M21.8M28.5M32.8M34.5M
Net Tangible Assets(190.5M)(180.4M)(209.3M)(254.1M)(228.7M)(240.1M)
Capital Surpluse2.8B2.9B2.9B3.0B3.4B2.8B

MannKind Corp Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense9.5M16.6M24.8M25.2M28.9M30.4M
Total Revenue65.1M75.4M99.8M199.0M228.8M240.2M
Gross Profit40.5M36.6M42.3M136.2M156.6M164.5M
Operating Income(24.8M)(53.5M)(68.9M)8.7M10.0M10.5M
Ebit(48.0M)(64.3M)(62.6M)10.6M12.2M12.8M
Research Development6.2M12.3M19.7M31.3M28.2M26.7M
Ebitda(45.0M)(61.1M)(56.3M)15.1M17.4M18.3M
Income Before Tax(57.5M)(80.9M)(87.4M)(10.4M)(11.9M)(12.5M)
Net Income(57.2M)(91.8M)(112.2M)(11.9M)(13.7M)(14.4M)
Income Tax Expense(218K)10.9M24.8M1.6M1.8M1.7M
Cost Of Revenue24.6M38.9M57.5M62.8M56.5M92.0M
Interest Income167K112K2.5M5.4M4.8M3.0M
Net Interest Income(9.3M)(16.5M)(22.3M)(19.7M)(17.7M)(18.6M)

MannKind Corp Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash36.9M57.0M(54.4M)168.7M194.0M203.7M
Free Cash Flow(32.9M)(73.2M)(88.3M)(8.3M)(9.6M)(10.1M)
Depreciation3.3M5.5M9.1M5.8M5.2M7.4M
Other Non Cash Items18.4M6.6M8.2M8.0M7.2M5.1M
Capital Expenditures4.8M11.5M7.6M42.4M38.2M40.1M
Net Income(57.2M)(80.9M)(87.4M)(11.9M)(13.7M)(14.4M)
End Period Cash Flow67.2M124.2M69.8M238.5M214.6M225.4M
Change To Inventory(1.3M)(4.1M)(5.7M)4.6M5.3M5.5M
Investments20M(137.1M)4.9M20.9M18.8M19.8M
Net Borrowings63.7M14.9M177.7M(18K)(20.7K)(19.7K)
Change To Netincome868K30.4M24.8M10.9M9.8M17.4M
Change Receivables504K(705K)(776K)(11.8M)(13.6M)(12.9M)

MannKind Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining MannKind Corp's current stock value. Our valuation model uses many indicators to compare MannKind Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MannKind Corp competition to find correlations between indicators driving MannKind Corp's intrinsic value. More Info.
MannKind Corp is regarded second in return on asset category among its peers. It is regarded fourth in profit margin category among its peers fabricating about  0.88  of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for MannKind Corp is roughly  1.13 . At present, MannKind Corp's Net Loss is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value MannKind Corp by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

MannKind Corp Systematic Risk

MannKind Corp's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MannKind Corp volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on MannKind Corp correlated with the market. If Beta is less than 0 MannKind Corp generally moves in the opposite direction as compared to the market. If MannKind Corp Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MannKind Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MannKind Corp is generally in the same direction as the market. If Beta > 1 MannKind Corp moves generally in the same direction as, but more than the movement of the benchmark.

MannKind Corp Thematic Clasifications

MannKind Corp is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Pharmaceutical ProductsView
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in MannKind Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MannKind Corp's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MannKind Corp growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.86

At present, MannKind Corp's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

MannKind Corp January 30, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of MannKind Corp help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MannKind Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of MannKind Corp based on widely used predictive technical indicators. In general, we focus on analyzing MannKind Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MannKind Corp's daily price indicators and compare them against related drivers.

Complementary Tools for MannKind Stock analysis

When running MannKind Corp's price analysis, check to measure MannKind Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MannKind Corp is operating at the current time. Most of MannKind Corp's value examination focuses on studying past and present price action to predict the probability of MannKind Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MannKind Corp's price. Additionally, you may evaluate how the addition of MannKind Corp to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Transaction History
View history of all your transactions and understand their impact on performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account